Cell Therapy
& Bispecifics
US Focus Meeting 2026
📍 Hilton Austin, 500 E 4th St, Austin, TX 78701
🗓️ March 6 - 7, 2026
Last Year's Highlights
Dear Colleagues and Friends,
We are delighted to extend our warmest invitation to the Cell Therapy & Bispecifics Focus Meeting 2026, to be held at on March 6 - 7, 2026.
Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing Cell Therapy & Bispecifics research and patient treatment.
This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.
Chairs of Cell Therapy & Bispecifics US Focus Meeting 2026:
Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX
Sattva Neelapu, MD
MD Anderson Cancer Center, Houston, TX
Noopur Raje, MD
Massachusetts General Hospital, Boston, MA
Supporters to be announced...
Interested in supporting this meeting? Get in contact:
alex.worthington@md-education.com
Agenda & Faculty
March 6, 2026 | Day 1
09:05 AM
Keynote 1: CAR-T Cell Therapy for Solid Tumors
GK
Giedre Krenciute, MD
City of Hope, Duarte, CA
Session I: Lymphoma
Moderated by:
Sattva Neelapu, MD
MD Anderson Cancer Center, Houston, TX
09:35 PM
Real-world Outcomes with CAR-T in LBCL
MH
Mehdi Hamadani, MD
Medical College of Wisconsin, Wauwatosa, WI
09:55 PM
Real-world Outcomes with Bispecifics in LBCL
BH
Brian Hill, MD
Cleveland Clinic, Cleveland, OH
10:15 PM
Immune Reconstitution After IEC Therapy in Lymphoma
RS
Roni Shouval, MD
Memorial Sloan Kettering Cancer Center, New York City, NY
Session II: Myeloma
Moderated by:
Noopur Raje, MD
Massachusetts General Hospital, Boston, MA
Tom Martin, MD
UCSF, San Francisco, CA
11:15 AM
Updates on approved CAR-T Cells and Real-world Data
Krina Patel, MD
MD Anderson Cancer Center, Houston, TX
11:15 AM
Updates on Approved Bispecifics and Real-world Data
Joshua Richter, MD
Icahn School of Medicine at Mount Sinai, New York, NY
11:55 AM
Treatment of Relapse After Bispecifics or CAR-T Cells: Belantamb and Other Approaches
Andrew Yee, MD
Massachusetts General Hospital, Boston, MA
Session III: Leukemia
Moderated by:
Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX
Marlise Luskin, MD
Dana-Farber Cancer Institute, Boston, MA
02:20 PM
CAR-T as Consolidation in Adult B-ALL
Ibrahim Aldoss, MD
City of Hope Comprehensive Cancer Center, Duarte, CA
02:40 PM
Towards Chemo-free/Chemo-lite Strategy in Adult ALL
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX
03:00 PM
How Do I Use CAR-T in Adult ALL
NF
Noelle Frey, MD
Penn Medicine, Philadelphia, PA
03:20 PM
CAR-T for AML. Progress and Pitfalls
Naval Daver, MD
MD Anderson Cancer Center, Houston, TX
Session IV: TBD
Moderated by:
Sonali Smith, MD
The University of Chicago Medicine, IL
04:20 PM
Is Follicular Lymphoma Curable with CAR-T or Bispecifics?
LL
Lori Leslie, MD
Hackensack Meridian Health, NJ
04:40 PM
In Favor of CAR-T
M. Lia Palomba, MD
Memorial Sloan Kettering Cancer Center, New York City, NY
04:50 PM
In Favor of Bispecifics
RB
Rajat Banerji, MD
Rutgers Cancer Institute, New Brunswick, NJ
Fellow Abstract Review Session I
Moderated by:
Sattva Neelapu, MD
MD Anderson Cancer Center, Houston, TX
05:20 PM
Abstract 1
TBD
KOL TBD
KOL TBD
05:30 PM
Abstract 2
TBD
KOL TBD
KOL TBD
March 7, 2026 | Day 2
09:05 AM
Keynote 2: Mechanisms and Treatment of Uncommon Toxicities After IEC Therapies
Samir Parekh, MD
Icahn School of Medicine at Mount Sinai, New York, NY
Session V: Myeloma
Moderated by:
Noopur Raje, MD
Massachusetts General Hospital, Boston, MA
Amrita Krishnan, MD
City of Hope Comprehensive Cancer Center, Duarte, CA
09:35 AM
Novel Bispecific and Trispecific Antibody Therapies and Combinations for Myeloma
DC
Diana Cirstea, MD
Massachusetts General Hospital, Boston, MA
09:55 AM
Novel CAR-T Cell Therapies for Myeloma Including Off-the-Shelf Allogeneic and In Vivo CARs
BP
Benjamin Puliafito, MD
Massachusetts General Hospital, Boston, MA
10:15 AM
Management of Toxicities for CAR-T Cells and Bispecifics in a Changing Landscape
Doris Hansen, MD
Moffitt Cancer Center, Tampa, FL
Session VI: Leukemia
Moderated by:
Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX
Marina Konopleva, MD
Albert Einstein College of Medicine, New York City, NY
11:15 AM
CAR-T for CLL. Is There a Cure Fraction?
TS
Tanya Siddiqi, MD
City of Hope, Duarte, CA
11:35 AM
CAR-T for T-ALL
Armin Ghobadi, MD
Washington University School of Medicine, St. Louis, MO
Session VII: Lymphoma
Moderated by:
RK
Reem Karmali, MD
Northwestern University Feinberg School of Medicine, Chicago, IL
02:10 PM
When Should We Use Bispecifics in Follicular Lymphoma?
RK
Reem Karmali, MD
Northwestern University Feinberg School of Medicine, Chicago, IL
02:30 PM
Novel CAR-T Therapies for LBCL
SD
Saurabh Dahiya, MD
Stanford Medicine, CA
02:50 PM
Novel CAR-T Targets for T-cell Lymphomas
Sattva Neelapu, MD
MD Anderson Cancer Center, Houston, TX
Session VIII: TBD
Moderated by:
Sairah Ahmed, MD
MD Anderson Cancer Center, Houston, TX
03:50 PM
Non-relapse Mortality After IEC Therapy
OO
Olalekan Oluwole, MD
Vanderbilt University Medical Center, Nashville, TN
04:00 PM
In Favor of Transplant
Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX
04:10 PM
In Favor of No Transplant
Marlise Luskin, MD
Dana-Farber Cancer Institute, Boston, MA
04:20 PM
In Favor of CAR-T
Sairah Ahmed, MD
MD Anderson Cancer Center, Houston, TX
04:30 PM
In Favor of Bispecifics
James Godfrey, MD
City of Hope, Duarte, CA
Alex Worthington
Project Manager
How long has Alex Worthington been in the business?
Alex Worthington has been with MD Education since 2024.
About Alex Worthington
As Assistant Project Manager, I work to ensure the Smooth running of events, assisting in the search process, outreach, organization, and the maintenance of any event. Having a Diverse Career background Working around the world, I pride myself on networking and creating positive relationships seamlessly with all attendees.
